Subcutaneous MabCampath (alemtuzumab) and oral Fludara (fludarabine phosphate) for the treatment of refractory or relapsed chronic lymphocytic leukemia in 2nd or 3rd line of treatment: A pilot trial (FLUSALEM) for the determination of safety, efficacy and molecular profiling for the prediction of response

Trial Profile

Subcutaneous MabCampath (alemtuzumab) and oral Fludara (fludarabine phosphate) for the treatment of refractory or relapsed chronic lymphocytic leukemia in 2nd or 3rd line of treatment: A pilot trial (FLUSALEM) for the determination of safety, efficacy and molecular profiling for the prediction of response

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2008

At a glance

  • Drugs Alemtuzumab; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FLUSALEM
  • Most Recent Events

    • 04 Jun 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov.
    • 10 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top